The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3

被引：1
|
作者：
O'Shaughnessy, Joyce [1 ]
Goetz, Matthew P. [2 ]
Sledge, George W. [3 ]
Martin, Miguel [4 ,5 ]
Lin, Yong [6 ]
Forrester, Tammy [6 ]
Smith, Ian C. [6 ]
Di Leo, Angelo [7 ]
Johnston, Stephen [8 ]
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[2] Mayo Clin, Rochester, MN USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[5] Univ Complutense, Madrid, Spain
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Hosp Prato, Prato, Italy
[8] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT099
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Fremanezumab in Different Racial and Ethnic Subgroups of Patients with Migraine: A Pooled Analysis of Phase 3 Studies
    Charleston, Larry
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Barash, Steve
    Lengil, Tamar
    Ojwang, Beryl
    Kim, Byung-Kun
    ANNALS OF NEUROLOGY, 2022, 92 : S42 - S43
  • [32] Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
    Smith, Jaclyn A.
    Birring, Surinder S.
    Dicpinigaitis, Peter, V
    McGarvey, Lorcan P.
    Morice, Alyn H.
    Pavord, Ian D.
    Satia, Imran
    Green, Stuart
    Iskold, Beata
    La Rosa, Carmen
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Muccino, David
    LUNG, 2022, 200 (04) : 423 - 429
  • [33] Effect of teriflunomide in subgroups defined by prior treatment: pooled analysis of the phase 3 TEMSO, TOWER, and TENERE studies
    Comi, G.
    Freedman, M. S.
    Meca-Lallana, J.
    Vermersch, P.
    Kim, B.
    Parajeles, A.
    Edwards, K.
    Gold, R.
    Overell, J.
    Korideck, H.
    Chavin, J.
    Poole, E.
    Coyle, P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 682 - 682
  • [34] Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
    Jaclyn A. Smith
    Surinder S. Birring
    Peter V. Dicpinigaitis
    Lorcan P. McGarvey
    Alyn H. Morice
    Ian D. Pavord
    Imran Satia
    Stuart Green
    Beata Iskold
    Carmen La Rosa
    Qing Li
    Allison Martin Nguyen
    Jonathan Schelfhout
    David Muccino
    Lung, 2022, 200 : 423 - 429
  • [35] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Takahashi, Masato
    Tokunaga, Eriko
    Mori, Joji
    Tanizawa, Yoshinori
    Van der Walt, Jan-Stefan
    Kawaguchi, Tsutomu
    Goetz, Matthew P.
    Toi, Masakazu
    BREAST CANCER, 2022, 29 (01) : 174 - 184
  • [36] Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 (vol 26, pg e53, 2020)
    Rugo, Hope S.
    Huober, Jens
    Garcia-Saenz, Jose A.
    Masuda, Norikazu
    Sohn, Joo Hyuk
    Andre, Valerie A. M.
    Barriga, Susana
    Cox, Joanne
    Goetz, Matthew
    ONCOLOGIST, 2021, 26 (03): : E522 - E522
  • [37] Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant
    Tolaney, Sara M.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Llombart-Cussac, Antonio
    Soliman, Hatem
    Litchfield, Lacey M.
    Wijayawardana, Sameera
    Forrester, Tammy
    Jansen, Valerie M.
    Sledge, George W.
    CANCER RESEARCH, 2019, 79 (13)
  • [38] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Masato Takahashi
    Eriko Tokunaga
    Joji Mori
    Yoshinori Tanizawa
    Jan-Stefan van der Walt
    Tsutomu Kawaguchi
    Matthew P. Goetz
    Masakazu Toi
    Breast Cancer, 2022, 29 : 174 - 184
  • [39] Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2-advanced breast cancer: Analysis of the MONARCH trials
    Rugo, H. S.
    Tolaney, S. M.
    Huober, J.
    Toi, M.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, G. W.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies
    Stroes, E.
    Robinson, J.
    Raal, F.
    Dufour, R.
    Sullivan, D.
    Blagden, M.
    Kassahun, H.
    Yang, J.
    Wasserman, S.
    Koren, M.
    EUROPEAN HEART JOURNAL, 2015, 36 : 307 - 308
12345